Showing 1421-1430 of 2046 results for "".
- Pioneering Ophthalmologist Spencer P. Thornton, MD, Dies at Age 90https://modernod.com/news/pioneering-ophthalmologist-spencer-p-thornton-md-dies-at-age-90/2477074/Spencer P. Thornton, MD, died at age 90 on October 26, 2019. A pioneer in the field of refractive surgery, Dr. Thornton served as the president of the ASCRS from 1997 to 1999 and received the society’s lifetime achievement award earlier this year. He was an internationally recognized speaker and
- Alcon Showcases New Vitrectomy Probe and Next Generation Ngenuity 3D Visualization System at ASRShttps://modernod.com/news/alcon-showcases-new-vitrectomy-probe-and-nextgeneration-ngenuity-3d-visualization-system-at-asrs/2476772/Alcon is introducing the Hypervit Dual Blade Vitrectomy Probe, the newest addition to the Constellation Vision System, at the American Society of Retina Specialists (ASRS) 2019 annual meeting taking place July 26-30 in Chicago. The company is also featuring its next generation Ngenuity 3D Visuali
- Clearside Biomedical Announces Multiple Oral Presentations to be Given at the ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-announces-multiple-oral-presentations-to-be-given-at-the-asrs-annual-meeting/2476742/Clearside Biomedical announced that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector targeting the suprachoroidal space will be given at the upcoming American Society of Retinal Specialists (ASRS) annual meeting taking place July 26-30, 2019 in Chicago. <
- Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During ASCRShttps://modernod.com/news/bausch-lomb-announces-new-scientific-analyses-featuring-surgical-and-pharmaceutical-products-will-be-presented-during-ascrs/2476509/Bausch + Lomb announced that 26 new scientific analyses, including 23 podium presentations and three posters, will feature the company’s surgical and pharmaceutical products during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from
- Johnson & Johnson Vision to Showcase New Products, Data, Educational Opportunities, and Charitable Giving at 2018 AAOhttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-products-data-educational-opportunities-and-charitable-giving-at-2018-aao/2479756/Johnson & Johnson Vision will showcase the company’s leadership in eye health, innovation and giving at the 2018 American Academy of Ophthalmology’s Annual Meeting (AAO) in Chicago, October 26-30. Johnson & Johnson Vision invented many of the treatments changing the trajectory of e
- Ellex to Host an AMD Roundtable During AAO 2018https://modernod.com/news/ellex-to-host-an-amd-roundtable-during-aao-2018/2479760/Ellex Medical Lasers Limited announced that it will partner with a panel of leading ophthalmologists to host a roundtable on age-related macular degeneration (AMD) on Friday, October 26, during the American Academy of Ophthalmology (AAO) meeting in Chicago. “Our goal is to start a serious
- Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45 Million Public Offering of Common Stockhttps://modernod.com/news/aerpio-pharmaceuticals-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-45-million-public-offering-of-common-stock/2480066/Aerpio Pharmaceuticals announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announce
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d
- Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trialhttps://modernod.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/RegeneRx Biopharmaceuticals announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up. ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after 2 weeks of
- American Academy of Ophthalmology Urges Members to Immediately Stop Routine Surgical and In-Office Visitshttps://modernod.com/news/american-academy-of-ophthalmology-urges-members-to-immediately-stop-routine-surgical-and-in-office-visits/2477412/Due to the COVID-19 pandemic, the American Academy of Ophthalmology (AAO) stated that all ophthalmologists cease providing any treatment other than urgent or emergent care immediately. The statement posted on the AAO website reads: “We now live and practice in a critically di